Castellanos-Rizaldos and colleagues compared this assay to the FDA approved companion diagnostic, cobas® EGFR Mutation Test v2 (Roche), that detects defined mutations within the EGFR gene from plasma cfDNA liquid biopsy samples of NSCLC patients and found increased sensitivity and specificity using the ExoDx EGFR assay which they attributed to the exRNA-based assay design[53]. Here, EGFR is linked to non-small cell lung carcinoma.